Loading...
Loading...
India's budesonide imports from UNITED STATES total $2.0M across 115 shipments from 15 foreign suppliers. ESPEE BIOPHARMA & FINECHEM LLC leads with $408.2K in import value; the top 5 suppliers together control 61.3% of this origin. Leading Indian buyers include CIPLA LIMITED. This corridor reflects India's pharmaceutical import demand for budesonide — a diversified sourcing base with multiple active suppliers from UNITED STATES.

ESPEE BIOPHARMA & FINECHEM LLC is the leading Budesonide supplier from UNITED STATES to India, with import value of $408.2K across 11 shipments. The top 5 suppliers — ESPEE BIOPHARMA & FINECHEM LLC, M/S. PAREXEL INTERNATIONAL, LUPIN RESEARCH INC, MSSPRING BIO SOLUTION, M/S. NORTH AMERICAN DISTRIBUTION CE — collectively account for 61.3% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ESPEE BIOPHARMA & FINECHEM LLC | $408.2K | 11 | 20.8% |
| 2 | M/S. PAREXEL INTERNATIONAL | $364.5K | 4 | 18.6% |
| 3 | LUPIN RESEARCH INC | $183.0K | 1 | 9.3% |
| 4 | MSSPRING BIO SOLUTION | $146.9K | 1 | 7.5% |
| 5 | M/S. NORTH AMERICAN DISTRIBUTION CE | $100.7K | 1 | 5.1% |
| 6 | ESPEE BIOPHARMA FINECHEM LLC | $98.1K | 2 | 5.0% |
| 7 | YOURWAY TRANSPORT INC | $89.3K | 1 | 4.6% |
| 8 | NEW LIFE MEDICALS (USA) INC. | $82.8K | 2 | 4.2% |
| 9 | ESPEE BIOPHARMA & FINECHEM LLC. | $66.7K | 2 | 3.4% |
| 10 | SPRING BIO SOLUTION | $60.3K | 6 | 3.1% |
| 11 | SPRING BIO SOLUTION. | $40.1K | 2 | 2.0% |
| 12 | AGRACE PHARMA | $37.9K | 3 | 1.9% |
| 13 | M/S.SPRING BIO SOLUTION | $37.2K | 1 | 1.9% |
| 14 | NEWLIFE MEDICALS (USA). INC. | $22.8K | 2 | 1.2% |
| 15 | AMNEAL PHARMACEUTICALS LLC | $22.8K | 4 | 1.2% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED | $679.6K | 26 | 34.6% |
| 2 | LUPIN LIMITED | $416.8K | 5 | 21.2% |
| 3 | CIPLA LIMITED. | $191.5K | 2 | 9.8% |
| 4 | SANDOZ PRIVATE LIMITED | $184.2K | 2 | 9.4% |
| 5 | ZYDUS LIFESCIENCES LIMITED | $143.1K | 7 | 7.3% |
| 6 | CLIANTHA RESEARCH LIMITED | $53.1K | 5 | 2.7% |
| 7 | DR.REDDY'S LABORATORIES LTD | $38.3K | 1 | 2.0% |
| 8 | MANKIND PHARMA LIMITED | $36.5K | 15 | 1.9% |
| 9 | CADILA HEALTHCARE LIMITED | $35.6K | 1 | 1.8% |
| 10 | AUROBINDO PHARMA LTD | $35.5K | 9 | 1.8% |
| 11 | VEEDA CLINICAL RESEARCH LIMITED | $21.8K | 3 | 1.1% |
| 12 | LUPIN LTD | $20.6K | 2 | 1.1% |
| 13 | RUBICON RESEARCH LIMITED | $19.2K | 1 | 1.0% |
| 14 | DR.REDDY'S LABORATORIES LIMITED | $16.9K | 1 | 0.9% |
| 15 | GLENMARK PHARMACEUTICALS LIMITED | $15.6K | 1 | 0.8% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Budesonide suppliers from UNITED STATES to India include ESPEE BIOPHARMA & FINECHEM LLC, M/S. PAREXEL INTERNATIONAL, LUPIN RESEARCH INC. The leading supplier is ESPEE BIOPHARMA & FINECHEM LLC with import value of $408.2K USD across 11 shipments. India imported Budesonide worth $2.0M USD from UNITED STATES in total across 115 shipments.
India imported Budesonide worth $2.0M USD from UNITED STATES across 115 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Budesonide sourced from UNITED STATES include CIPLA LIMITED, LUPIN LIMITED, CIPLA LIMITED.. The largest buyer is CIPLA LIMITED with $679.6K in imports across 26 shipments.
The total value of Budesonide imports from UNITED STATES to India is $2.0M USD, across 115 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
115 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists